TVTX
Bearish signalScored 2026-10-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Travere Therapeutics, Inc.
- Nom
- Travere Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $4.9B
- Employés
- 497
- PDG
- Eric Dube
- Site web
- https://www.travere.com
- Marché
- MAZEMLYSPHARPROK
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 663 735 titres (~39 544 518,89 $ US)
- Insiders
- Dube Eric MMeckler Jeffrey A
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$21,119,607
Avg sell (VWAP, 90d window) $61.69 vs last close $49.97 (-19.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$16,763,594 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Liquid $102,817,313/day · 20d vol
- Last synced
-
2026-10-26 21:11:04
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Dube Eric M | Sell · S | 78,400 | $55.02 | $4,313,403 | Form 4 |
| 2026-09-17 | Dube Eric M | Sell · S · 10b5-1 | 6,802 | $64.95 | $441,795 | Form 4 |
| 2026-09-17 | Heerma Peter | Sell · S · 10b5-1 | 8,282 | $65.07 | $538,917 | Form 4 |
| 2026-09-16 | Dube Eric M | Sell · S · 10b5-1 | 96,125 | $63.64 | $6,117,289 | Form 4 |
| 2026-09-16 | Heerma Peter | Sell · S · 10b5-1 | 79,113 | $63.65 | $5,035,906 | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Sell · S · 10b5-1 | 65,104 | $63.12 | $4,109,397 | Form 4 |
| 2026-09-15 | Calvin Sandra | Sell · S · 10b5-1 | 300 | $63.66 | $19,099 | Form 4 |
| 2026-09-15 | Cline Christopher R. | Sell · S · 10b5-1 | 400 | $65.31 | $26,124 | Form 4 |
| 2026-09-15 | Dube Eric M | Sell · S · 10b5-1 | 270 | $65.31 | $17,634 | Form 4 |
| 2026-09-15 | Heerma Peter | Sell · S · 10b5-1 | 1,431 | $65.31 | $93,458 | Form 4 |
| 2026-09-15 | Inrig Jula | Sell · S · 10b5-1 | 400 | $65.31 | $26,124 | Form 4 |
| 2026-09-15 | REED ELIZABETH E | Sell · S · 10b5-1 | 300 | $65.31 | $19,593 | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Sell · S · 10b5-1 | 270 | $65.31 | $17,634 | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Sell · S · 10b5-1 | 3,100 | $68.09 | $211,073 | Form 4 |
| 2026-09-02 | Cline Christopher R. | Sell · S | 642 | $66.37 | $42,610 | Form 4 |
| 2026-08-18 | LYONS GARY A | Sell · S · 10b5-1 | 900 | $63.86 | $57,470 | Form 4 |
| 2026-08-17 | LYONS GARY A | Sell · S · 10b5-1 | 500 | $64.16 | $32,081 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
TVTX combines a weak catalyst score (15) driven by heavy insider selling (~$39.5M, zero buys), a departing CEO, and an active litigation probe, with fragile fundamentals reflected in negative free cash flow, high…
The first sentence of the analysis written for TVTX on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 2.74 · operating margin -13% — readings disagree
Suggested stop 33.69, nearest stored support minus 0.5 ATR(32.6% under the last close). Reward/risk to the next stored resistance is 0.34. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-12 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 142,580 shares of its common stock. These induceme.
- 2026-10-02 Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)."The final SPARTAN analysis provides a compelling picture of what''s possible whe.
- 2026-09-30 Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders.
- 2026-09-24 Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell? Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report)''s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $62.86, but opened at $60.37. Travere Therapeutics shares last traded at $61.2310, with a volume of 306,408 shares trading hands. Analyst Upgrades and Downgrades Several brokerages have recently issued reports
- 2026-09-23 Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Paten
- 2026-09-23 Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain me.
- 2026-09-21 Travere Therapeutics Announces Planned Chief Executive Officer Transition SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company''s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and.
- 2026-09-20 Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) EVP Peter Heerma sold 8,282 shares of the company''s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $65.07, for a total value of $538,909.74. Following the sale, the executive vice president owned 117,066 shares of the company''s stock,
- 2026-09-20 Travere Therapeutics (NASDAQ:TVTX) Insider Sells $2,337,750.00 in Stock Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) insider Elizabeth Reed sold 37,500 shares of the firm''s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total transaction of $2,337,750.00. Following the sale, the insider owned 105,389 shares in the company, valued
- 2026-09-17 Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere''s website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.About Travere TherapeuticsAt Travere Therapeutics, we are in rare.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | |
| Ebit Margin | -7.9% | -132.7% | -251.2% | -292.5% | -149.6% | |
| Ebitda Margin | 4.5% | -114.0% | -224.6% | -273.5% | -139.9% | |
| Operating Profit Margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | |
| Pretax Profit Margin | -10.0% | -137.5% | -259.0% | -302.5% | -164.5% | |
| Continuous Operations Profit Margin | -10.2% | -137.5% | -259.1% | -302.8% | -164.8% | |
| Net Profit Margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | |
| Bottom Line Profit Margin | -10.2% | -137.9% | -76.7% | -254.4% | -136.6% | |
| Current Ratio | 2.736 | 2.076 | 3.467 | 3.422 | 4.697 | |
| Quick Ratio | 2.700 | 2.045 | 3.414 | 3.390 | 4.638 | |
| Solvency Ratio | 0.072 | -0.520 | -0.124 | -0.409 | -0.353 | |
| Cash Ratio | 0.582 | 0.292 | 0.327 | 0.434 | 1.336 | |
| Price To Earnings Ratio | -68.232 | -4.270 | -5.993 | -4.812 | -10.312 | |
| Price To Earnings Growth Ratio | 0.791 | -0.025 | 0.091 | -0.107 | 0.667 | |
| Forward Price To Earnings Growth Ratio | 0.791 | -0.025 | 0.091 | -0.107 | 0.667 | |
| Price To Earnings Diluted Ratio | -68.232 | -4.270 | -5.993 | -4.812 | -10.312 | |
| Price To Earnings Diluted Growth Ratio | 0.791 | -0.025 | 0.091 | -0.107 | 0.667 | |
| Price To Book Ratio | 29.686 | 23.262 | 3.325 | 31.291 | 6.147 | |
| Price To Sales Ratio | 6.946 | 5.894 | 4.597 | 12.250 | 14.087 | |
| Price To Free Cash Flow Ratio | -167.319 | -4.058 | -2.076 | -6.246 | -47.690 | |
| Price To Operating Cash Flow Ratio | 90.218 | -5.787 | -2.384 | -7.198 | -125.554 | |
| Debt To Assets Ratio | 0.543 | 0.676 | 0.513 | 0.606 | 0.337 | |
| Debt To Equity Ratio | 2.863 | 6.798 | 2.016 | 9.509 | 0.867 | |
| Debt To Capital Ratio | 0.741 | 0.872 | 0.668 | 0.905 | 0.464 | |
| Long Term Debt To Capital Ratio | 0.731 | 0.840 | 0.653 | 0.898 | 0.429 | |
| Financial Leverage Ratio | 5.270 | 10.057 | 3.929 | 15.696 | 2.571 | |
| Working Capital Turnover Ratio | 1.988 | 0.712 | 0.371 | 0.273 | 0.340 | |
| Operating Cash Flow Ratio | 0.236 | -1.183 | -1.574 | -1.310 | -0.119 | |
| Operating Cash Flow Sales Ratio | 0.077 | -1.018 | -1.928 | -1.702 | -0.112 | |
| Free Cash Flow Operating Cash Flow Ratio | -0.539 | 1.426 | 1.149 | 1.152 | 2.633 | |
| Debt Service Coverage Ratio | 1.975 | -3.329 | -28.804 | -27.214 | -9.393 | |
| Interest Coverage Ratio | -5.845 | -28.960 | -34.245 | -29.037 | -10.132 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -3.458 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.115 | -0.591 | -0.692 | -0.457 | -0.056 | |
| Capital Expenditure Coverage Ratio | 0.650 | -2.346 | -6.733 | -6.567 | -0.612 | |
| Dividend Paid And Capex Coverage Ratio | 0.650 | -2.346 | -6.733 | -6.567 | -0.612 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 164.033 | -6.462 | -3.109 | -5.633 | -10.590 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.9% | ▲1.2% | ▲1.9% |
| Ebit Margin | -7.8% | ▲124.8% | ▲158.9% |
| Ebitda Margin | 4.5% | ▲118.5% | ▲154.0% |
| Operating Profit Margin | -12.8% | ▲126.1% | ▲159.7% |
| Pretax Profit Margin | -10.0% | ▲127.4% | ▲164.7% |
| Continuous Operations Profit Margin | -10.2% | ▲127.3% | ▲164.7% |
| Net Profit Margin | -5.2% | ▲132.7% | ▲117.0% |
| Bottom Line Profit Margin | -10.2% | ▲127.7% | ▲112.9% |
| Current Ratio | 2.736 | ▲0.661 | ▼-0.543 |
| Quick Ratio | 2.700 | ▲0.655 | ▼-0.538 |
| Solvency Ratio | 0.072 | ▲0.591 | ▲0.339 |
| Cash Ratio | 0.582 | ▲0.290 | ▼-0.012 |
| Price To Earnings Ratio | -68.232 | ▼-63.962 | ▼-49.508 |
| Price To Earnings Growth Ratio | 0.791 | ▲0.816 | ▲0.507 |
| Forward Price To Earnings Growth Ratio | 0.791 | ▲0.816 | ▲0.507 |
| Price To Earnings Diluted Ratio | -68.232 | ▼-63.962 | ▼-49.508 |
| Price To Earnings Diluted Growth Ratio | 0.791 | ▲0.816 | ▲0.507 |
| Price To Book Ratio | 29.686 | ▲6.424 | ▲10.944 |
| Price To Sales Ratio | 6.946 | ▲1.053 | ▼-1.808 |
| Price To Free Cash Flow Ratio | -167.319 | ▼-163.261 | ▼-121.841 |
| Price To Operating Cash Flow Ratio | 90.218 | ▲96.005 | ▲100.359 |
| Debt To Assets Ratio | 0.543 | ▼-0.133 | ▲0.008 |
| Debt To Equity Ratio | 2.863 | ▼-3.935 | ▼-1.548 |
| Debt To Capital Ratio | 0.741 | ▼-0.131 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.731 | ▼-0.109 | ▲0.021 |
| Financial Leverage Ratio | 5.270 | ▼-4.786 | ▼-2.234 |
| Working Capital Turnover Ratio | 1.988 | ▲1.276 | ▲1.252 |
| Operating Cash Flow Ratio | 0.236 | ▲1.419 | ▲1.026 |
| Operating Cash Flow Sales Ratio | 0.077 | ▲1.095 | ▲1.014 |
| Free Cash Flow Operating Cash Flow Ratio | -0.539 | ▼-1.965 | ▼-1.703 |
| Debt Service Coverage Ratio | 1.975 | ▲5.305 | ▲15.328 |
| Interest Coverage Ratio | -5.845 | ▲23.114 | ▲15.799 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲3.458 | ▲0.692 |
| Operating Cash Flow Coverage Ratio | 0.115 | ▲0.706 | ▲0.451 |
| Capital Expenditure Coverage Ratio | 0.650 | ▲2.996 | ▲3.772 |
| Dividend Paid And Capex Coverage Ratio | 0.650 | ▲2.996 | ▲3.772 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 164.033 | ▲170.494 | ▲136.385 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.41B | $1.37B | $667.7M | $1.34B | $1.86B | |
| Enterprise value | $3.64B | $1.72B | $1.01B | $1.69B | $1.95B | |
| EV / Sales | 7.43x | 7.37x | 6.98x | 15.41x | 14.82x | |
| EV / Op. cash flow | 96.46x | -7.23x | -3.62x | -9.05x | -132.06x | |
| EV / Free cash flow | -178.89x | -5.07x | -3.15x | -7.86x | -50.16x | |
| EV / EBITDA | 164.03x | -6.46x | -3.11x | -5.63x | -10.59x | |
| Net debt / EBITDA | 10.61x | -1.29x | -1.06x | -1.16x | -0.52x | |
| Current ratio | 2.74x | 2.08x | 3.47x | 3.42x | 4.70x | |
| Income quality | -1.48x | 0.74x | 0.74x | 0.56x | 0.07x | |
| Graham net-net | -$1 | -$2 | -$0 | -$3 | $2 | |
| Tax burden | 51.8% | 100.3% | 29.6% | 84.1% | 83.0% | |
| Interest burden | 127.9% | 103.6% | 103.1% | 103.4% | 110.0% | |
| Working capital | $277.7M | $216.0M | $438.9M | $344.3M | $458.7M | |
| Invested capital | $405.4M | $339.6M | $568.9M | $471.4M | $641.4M | |
| Return on assets | -4.2% | -54.1% | -14.1% | -41.4% | -23.2% | |
| Operating ROA | -10.5% | -46.8% | -53.1% | -44.1% | -28.8% | |
| Return on tangible assets | -5.2% | -65.6% | -16.3% | -48.4% | -28.7% | |
| Return on equity | -22.2% | -544.3% | -55.5% | -649.9% | -59.6% | |
| Return on invested capital | -13.9% | -69.3% | -63.0% | -59.8% | -30.4% | |
| Return on capital employed | -14.1% | -82.3% | -63.5% | -60.3% | -30.6% | |
| Earnings yield | -0.7% | -23.4% | -16.7% | -20.8% | -9.7% | |
| Free cash flow yield | -0.6% | -24.6% | -48.2% | -16.0% | -2.1% | |
| Capex / Op. cash flow | 153.9% | -42.6% | -14.9% | -15.2% | -163.3% | |
| Capex / Depreciation | 95.7% | 232.4% | 107.9% | 136.9% | 189.5% | |
| Capex / Sales | 11.9% | 43.4% | 28.6% | 25.9% | 18.3% | |
| SG&A / Sales | 68.7% | 113.3% | 182.8% | 180.4% | 95.8% | |
| R&D / Sales | 42.0% | 121.2% | 168.7% | 207.7% | 152.6% | |
| Stock comp / Sales | 9.1% | 15.8% | 30.5% | 34.8% | 22.4% | |
| Intangibles / Total assets | 18.7% | 17.5% | 13.2% | 14.4% | 19.1% | |
| Days sales outstanding | 60d | 42d | 53d | 56d | 44d | |
| Days payables outstanding | 876d | 1109d | 1329d | 1428d | 1448d | |
| Operating cycle | 267d | 335d | 353d | 429d | 743d | |
| Cash conversion cycle | -609d | -775d | -975d | -999d | -705d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years